Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
Primary Objective: The primary objective is to determine the incidence of complete remission (CR) at day +30 post HSCT after Clofarabine followed by Hematopoietic Stem Cell Transplant (HSCT) using Fludarabine, Busulfan (FluBu), and total body irradiation (TBI) with Post-Transplant Cyclophosphamide (PTCy). Secondary Objectives: - To determine disease-free survival (DFS) and overall survival (OS) following HSCT using PTCy. - To determine the rate of non-relapse related mortality (NRM) at day 100. - To determine the incidence and severity of acute and chronic graft versus host disease (GVHD). - To determine the rate of engraftment.